Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment crawled date : 2021 - 10 - 27 save search
UPDATE – Sorrento Announces Encouraging Results From Two Phase 2 Studies of Abivertinib For Treatment Of Hospitalized Severe COVID-19 Patients
Published: 2021-10-27 (Crawled : 20:00) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 0.3%
H: 5.22%
C: 5.07%
covid treatment phase 2 results
Sorrento Announces Encouraging Results From Two Phase 2 Studies of Abivertinib For Treatment Of Hospitalized Severe COVID-19 Patients
Published: 2021-10-27 (Crawled : 19:00) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 0.3%
H: 5.22%
C: 5.07%
covid treatment phase 2 results
Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Tissue Sarcoma
Published: 2021-10-27 (Crawled : 13:15) - biospace.com/
MNPR | News | $0.688 5.04% 4.8% 78K
|
Health Technology
|
| O: 4.88%
H: 7.64%
C: 3.31%
treatment phase 1 phase 1b trial phase 2b soft tissue
Pasithea Therapeutics Announces Successful Treatment of First Patients in the UK with Ketamine Infusion Therapy– Pasithea Clinics
Published: 2021-10-27 (Crawled : 12:15) - biospace.com/
KTTA | $7.15 -1.19% 700
|
|
| O: 2.95%
H: 43.37%
C: 6.09%
treatment therapy ketamine depression
Biohaven Enrolls Phase 1a/1b Clinical Trial of BHV-1100, Lead Asset from its ARM™ (Antibody Recruiting Molecule) Platform, in Combination with NK Cell Therapy for the Treatment of Multiple Myeloma
Published: 2021-10-27 (Crawled : 12:00) - prnewswire.com
BHVN | News 0 d | $42.16 -4.25% 0.85% 3.7M
|
Health Technology
|
| O: 0.21%
H: 0.1%
C: -3.26%
treatment phase 1 therapy antibody trial phase 1b enroll
AZSTARYS®, An Innovative ADHD Treatment Developed by KemPharm, to be Featured in a Poster Presentation at the 2021 Psych Congress
Published: 2021-10-27 (Crawled : 12:00) - kempharm.com
KMPH | $5.46 6.04% 0
|
Manufacturing
|
| O: -0.39%
H: 2.25%
C: -1.17%
presentation treatment adhd
Merck Presents New Data from Ongoing Phase 2b Clinical Trial Evaluating Efficacy and Safety of Investigational Islatravir in Combination With Doravirine Through 144 Weeks for HIV-1 Treatment at EACS 2021
Published: 2021-10-27 (Crawled : 12:00) - biospace.com/
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
|
| O: 0.71%
H: 0.0%
C: -1.14%
treatment phase 2 ongoing phase 2b trial hiv
Pasithea Therapeutics Announces Successful Treatment of First Patients in the UK with Ketamine Infusion Therapy
Published: 2021-10-27 (Crawled : 12:00) - globenewswire.com
KTTA | $7.15 -1.19% 700
|
|
| O: 2.95%
H: 43.37%
C: 6.09%
treatment therapy ketamine
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.